R. Arranz

Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients

Jacobo Rogado, J.M. Sánchez-Torres, Nuria Romero-Laorden et al. · European Journal of Cancer · 2019 · 261 citations

Life Sciences, Immunology, Oncology +17

Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

Anna Sureda, R. Arranz, A Iriondo et al. · Journal of Clinical Oncology · 2001 · 231 citations

Medicine, Clinical Sciences, Oncology +15

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

Anna Sureda, M. Constans, A Iriondo et al. · Annals of Oncology · 2005 · 220 citations · Full text

Medicine, Hematology, Oncology +17

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Anna Sureda, Carmen Canals, R. Arranz et al. · Haematologica · 2011 · 213 citations · Full text

Medicine, Immunology, Oncology +17

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone

Adrían Alegre, JF Tomás, Carmen Martínez‐Chamorro et al. · Bone Marrow Transplantation · 1997 · 134 citations · Full text

Medicine, Hematology, Oncology +17